STR-P004 for relapsed/refractory B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called STR-P004 for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment, and you have few other options.
- Your leukemia cells must test positive for CD19 (a specific protein).
- You have not had CAR-T or other gene-modified cell therapy in the last 6 months.
- You have a moderate level of cancer cells in your bone marrow (at least 5%).
- Your organs (like liver, kidneys, heart, and lungs) are working well enough, and you are generally up and about (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
This trial tests a new oral drug called SP-3164 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least 2 prior treatments. It aims to see if the drug is safe and effective.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests a new drug called TRS005 for people with a specific type of lymphoma (CD20-positive DLBCL) that has come back or not responded to at least two prior treatments. It is for those who cannot have a stem cell transplant and aims to see if the drug can shrink tumors and help control the disease.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.